Resmetirom is the first treatment ever approved for fatty liver disease. Could GLP1 based obesity/diabetes medications have similar benefits?
Learn more: https://drsue.ca/2024/03/first-medication-ever-approved-to-treat-fatty-liver-disease-how-will-glp1-based-obesity-diabetes-medications-stack-up/
Any medical discussion on this podcast is intended to be of a general nature only, and is intended for a Canadian audience. This podcast is not designed to give specific medical advice to patients, nor to their health care providers. If you have a medical problem you should consult your own physician for advice specific to your own situation. Postings on this podcast represent the personal opinions of Dr. Sue Pedersen. They are not representative of, nor endorsed by, Alberta Health Services. This podcast is intended for the Canadian general public as well as Canadian allied health professionals.
Resmetirom is the first treatment ever approved for fatty liver disease. Could GLP1 based obesity/diabetes medications have similar benefits?
Learn more: https://drsue.ca/2024/03/first-medication-ever-approved-to-treat-fatty-liver-disease-how-will-glp1-based-obesity-diabetes-medications-stack-up/
Any medical discussion on this podcast is intended to be of a general nature only, and is intended for a Canadian audience. This podcast is not designed to give specific medical advice to patients, nor to their health care providers. If you have a medical problem you should consult your own physician for advice specific to your own situation. Postings on this podcast represent the personal opinions of Dr. Sue Pedersen. They are not representative of, nor endorsed by, Alberta Health Services. This podcast is intended for the Canadian general public as well as Canadian allied health professionals.